Antoxerene Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $1.5M
Latest Deal Amount
  • Investors
  • 2

Antoxerene General Information


Developer of drug discovery platform intended to provide study on protein interactions that drive the survival of toxic senescent cells. The company is onto the onset and progression of several age-associated diseases and to identify and develop novel compounds to selectively destroy these cells and restore tissue function, enabling the patients to reap the benefits of pathways of aging.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • 2521 U.S. Route 11
  • NY 13084
  • United States
+1 (518) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Antoxerene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 25-Aug-2017 $1.5M 00.00 00.00 Completed Pre-Clinical Trials

Antoxerene Cap Table

To view Antoxerene‘s complete cap table, request access »
Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 00.000

Antoxerene Executive Team (2)

Name Title Board Seat Contact Info
Kelsey Moody Ph.D Chief Executive Officer & President
Aaron Wolfe Ph.D Chief Operating Officer

Antoxerene Board Members (1)

Name Representing Role Since
Roger Bagg Self Board Member 000 0000

Antoxerene Investors (2)

To view Antoxerene‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kizoo Technology Capital Venture Capital Minority 000 0000 000000 0
SENS Research Foundation Other Minority 000 0000 000000 0

Antoxerene Investments (1)

To view Antoxerene‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 12-Jul-2018 00000 0000000 0000 Biotechnology 000000 00000 00.0

Ready to get started?

Request a free trial